Who are SAB Biotherapeutics, Inc.'s main suppliers?

SAB Biotherapeutics, Inc. (SABS) key suppliers include: DAKOTA-AG-PROPERTIES, EMERGENT, FORTREA, Biodexa Pharmaceuticals Plc, Emergent BioSolutions Inc.. View the full supplier network at chainsifter.com/chain/SABS.

Who are SAB Biotherapeutics, Inc.'s major customers?

SAB Biotherapeutics, Inc. (SABS) key customers include: Biodexa Pharmaceuticals Plc, Emergent BioSolutions Inc., Emergent BioSolutions Inc., Sanofi, Sanofi and 3 more. View the full customer network at chainsifter.com/chain/SABS.

What sector is SAB Biotherapeutics, Inc. in?

SAB Biotherapeutics, Inc. (SABS) operates in the general sector. ChainSifter tracks its verified supply chain relationships including suppliers, customers, and strategic partners.

SAB Biotherapeutics, Inc. Suppliers, Customers & Supply Chain (SABS)

5Suppliers

8Customers

2Debt Items

20Related Chains

Source-Backed Evidence Depth

SAB Biotherapeutics, Inc. (SABS) is shown with relationship data already present in ChainSifter's database. Counts below come from stored supply-chain records and filing/source URLs where available; missing source URLs are not filled in or estimated.

16Total relationships

3Distinct source URLs

6High confidence

0.770Average confidence

2026-10-28Latest database update

ChainSifter does not infer unreported suppliers, customers, ownership, acquisitions, debt exposure, revenue dependency, or future supply-chain events on this public page.

SAB Biotherapeutics, Inc. Suppliers

Ticker	Name	Confidence	Evidence
DAKOTA-AG-PROPERTIES	DAKOTA-AG-PROPERTIES	92%	In December 2018, the Company entered into a finance lease with Dakota Ag Properties for a new animal facility which includes the surrounding land.
EMERGENT	EMERGENT	90%	Emergent has the sole and exclusive right to manufacture the Product during the term of the MSA
FORTREA	FORTREA	90%	The Company expects to make ongoing payments to Fortrea over the next 12 to 18 months in connection with services provided by Fortrea, as well as clinical trial site and other pass-through costs rela…
BDRX	Biodexa Pharmaceuticals Plc	72%	Reciprocal relationship from BDRX graph: Reciprocal relationship from SABS graph: Reciprocal relationship from BDRX graph: ddition of additional warnings, contraindications or other safety informatio…
EBS	Emergent BioSolutions Inc.	72%	Reciprocal relationship from EBS graph: Reciprocal relationship from SABS graph: Reciprocal relationship from EBS graph: Reciprocal relationship from SABS graph: Reciprocal relationship from EBS grap…

SAB Biotherapeutics, Inc. Customers

Ticker	Name	Confidence	Evidence
BDRX	Biodexa Pharmaceuticals Plc	72%	Reciprocal relationship from BDRX graph: Reciprocal relationship from SABS graph: Reciprocal relationship from BDRX graph: Reciprocal relationship from SABS graph: Reciprocal relationship from BDRX g…
EBS	Emergent BioSolutions Inc.	72%	Reciprocal relationship from EBS graph: Reciprocal relationship from SABS graph: Reciprocal relationship from EBS graph: Reciprocal relationship from SABS graph: gal activity. Misconduct by these par…
EBS	Emergent BioSolutions Inc.	72%	gal activity. Misconduct by these parties could include intentional, reckless or negligent conduct or disclosure of unauthorized activities to us that violates: (i) the rules and regulations of the F…
SNYNF	Sanofi	72%	ct pipeline and that may outperform or be more competitive than our products. For example, there are multiple products that may be competitive with SAB-142 for T1D such as animal-derived polyclonal b…
SNYNF	Sanofi	72%	Reciprocal relationship from SNYNF graph: Reciprocal relationship from SABS graph: ct pipeline and that may outperform or be more competitive than our products. For example, there are multiple produc…
BIG-CYPRESS-HOLDINGS-LLC	BIG-CYPRESS-HOLDINGS-LLC	62%	reference to the quoted market price. The Public Warrants were classified as a Level 1 fair value measurement, due to the use of the quoted market price, and the Private Placement Warrants held priva…
EMERGENT-BIOSOLUTIONS-CANADA-INC	EMERGENT-BIOSOLUTIONS-CANADA-INC	62%	gal activity. Misconduct by these parties could include intentional, reckless or negligent conduct or disclosure of unauthorized activities to us that violates: (i) the rules and regulations of the F…
UBS-SECURITIES-LLC	UBS-SECURITIES-LLC	62%	ctuate on a quarterly and annual basis, which may result in a decline in our stock price if such fluctuations result in a failure to meet the expectations of securities analysts or investors. Our ope…

SAB Biotherapeutics, Inc. Debt Obligations

Instrument	Description	Confidence	Evidence
SABS-DEBT-12349	Warrants outstanding: 2753246	90%	xbrl warrant detail from xbrl 2026-03-31.
SABS-DEBT	Debt stack $6.2M	90%	Market cache reports total debt of $6.2M.

SAB Biotherapeutics, Inc. Acquisitions

No acquisitions on recordNo completed or pending acquisitions found in our database for SAB Biotherapeutics, Inc..

SAB Biotherapeutics, Inc. Ownership

Holder	Name	Confidence	Evidence
SABS-OWNER-VIVO-CAPITAL-LLC	Vivo Capital, LLC	90%	13F overlay lists Vivo Capital, LLC as top holder; 79 tracked holders.

SAB Biotherapeutics, Inc. Extended Supply Chain Network

Ticker	Name	Chain Index	Hops	Relationship Types
REGN	Regeneron Pharmaceuticals, Inc.	100.00	2
GRDX	GridAI Technologies Corp.	100.00	2
CALC	CalciMedica, Inc.	100.00	2
CTMX	CytomX Therapeutics, Inc.	100.00	2
CYTOF	Altamira Therapeutics Ltd.	100.00	2
BDRX	Biodexa Pharmaceuticals Plc	100.00	1	['customer', 'supplier']
ANL	Adlai Nortye Ltd.	100.00	2
ATOS	Atossa Therapeutics, Inc.	100.00	2
BLRX	BioLineRx Ltd.	100.00	2
ANRO	Alto Neuroscience, Inc.	100.00	2
CCEP	Coca-Cola Europacific Partners PLC	100.00	2
DSGN	Design Therapeutics, Inc.	100.00	2
AZN	AstraZeneca PLC	100.00	2
ALXO	ALX Oncology Holdings Inc.	100.00	2
BIOA	BioAge Labs, Inc.	100.00	2
DBVTF	DBV TECHNOLOGIES	100.00	2
CYTK	Cytokinetics, Incorporated	100.00	2
EDIT	Editas Medicine, Inc.	100.00	2
CBIO	Crescent Biopharma, Inc.	100.00	2
ADAG	Adagene Inc.	100.00	2

SAB Biotherapeutics, Inc. Supply Chain